PREVIEW ASH 2026 — New Orleans, Dec 12–15: the abstracts hematologists are watching, top voices and trial buzz See the ASH 2026 preview →
KOL Pulse - Trial Profile

MDT-BRIDGE Trial

MDT-BRIDGE (NCT05925530) is AstraZeneca's phase II adaptive study in resectable and borderline-resectable stage IIB–IIIB NSCLC: 1–2 cycles of neoadjuvant durvalumab plus chemotherapy, then multidisciplinary reassessment routes each patient to surgery or definitive chemoradiotherapy, followed by adjuvant or consolidation durvalumab. Presented at WCLC 2026 (OA04.02, Martin Reck): 74.6% overall resection rate, 96.2% R0, pCR 27.3%, and 12-month EFS of 90.1% in the resectable cohort.

Phase II · NCT05925530 Sponsor: AstraZeneca ⚠️ Neoadjuvant strategy — investigational WCLC 2026 · OA04.02 · Martin Reck Resectable + borderline-resectable IIB–IIIB

MDT-BRIDGE at a Glance

Design

Adaptive phase II: 1–2 cycles of neoadjuvant durvalumab + platinum chemotherapy, then MDT reassessment — surgery if resectable, definitive chemoradiotherapy if not — followed by adjuvant durvalumab (post-surgery) or consolidation durvalumab (post-CRT). (Presented WCLC 2026 OA04.02; verbatim KOL captures)

Results — with denominators

Of 142 treated patients (full analysis set): 74.6% underwent resection, and 96.2% OF THOSE RESECTED achieved R0; pCR 27.3% (full analysis set); 12-month EFS 90.1% among patients deemed resectable at MDT reassessment; 92.3% of all patients received curative-intent surgery or CRT; 76% of borderline-resectable patients converted to resectable. (Presented data via the verbatim physician captures on this page: Patil, Özkerim, Horinouchi, Díaz-García)

Why it matters

Resectability becomes a treatment-modifiable state assessed after induction rather than a fixed baseline call — the study's core concept per the physicians discussing it. (Verbatim KOL posts)

Regulatory status

⚠️ The MDT-BRIDGE strategy is investigational. Durvalumab (Imfinzi) is approved in other NSCLC settings (unresectable stage III consolidation per PACIFIC; perioperative per AEGEAN); this bridging paradigm is not an approved regimen. (FDA labeling context)

Safety

Perioperative morbidity and treatment-related adverse-event data from OA04.02 are NOT reproduced on this page — our coverage reports the presented efficacy and surgical outcomes only. Consult the primary presentation for the safety tables before drawing risk-benefit conclusions. (Editorial disclosure)

KOL pulse

Urs Weber: “I really like the adaptive design of MDT-Bridge.” Yago Garitaonaindía: “Compelling results” — “Stop calling full resectability upfront: assess it after neoadjuvant chemo-IO, when the tumour has already shown you what it does.”

KOLs Discussing MDT-BRIDGE

Stephen V Liu, MD
Stephen V Liu, MD
@StephenVLiu
5,588 impressions
Hidehito HORINOUCHI
Hidehito HORINOUCHI
@HHorinouchi
2,604 impressions
Uğur Özkerim
Uğur Özkerim
@UOzkerim
1,453 impressions
MV Chandrakanth
MV Chandrakanth
@ChandrakanthMv
1,287 impressions
Diego A. Díaz-García
Diego A. Díaz-García
@diegoadiazg
718 impressions
Tejas Patil
Tejas Patil
@TejasPatilMD
671 impressions
Yago Garitaonaindía
Yago Garitaonaindía
@YGaritaonaindia
1,064 impressions

Key Slides & Data

Slides shared by global KOLs, mirrored to our CDN; slide text panels are verbatim Textract OCR.

Stephen V Liu, MD
Stephen V Liu, MD@StephenVLiu
MDT-BRIDGE — shared slides
WCLC 2026 · 2026-09-13
View on X
[Slide 1] IASLC 2026 World Conference on Lung Cancer I F SEPTEMBER 12 - 15, 2026 I SEOUL, REPUBLIC OF KOREA KALC SCIENCE WITHOUT BOUNDARIES: UNITING THE WORLD AGAINST THORACIC CANCER --- [Slide 2] IASLC 2026 World Conference SEPTEMBER 12 - 15, 2026 07 min 29s on Lung Cancer SEOUL, REPUBLIC OF KOREA MDT-BRIDGE study design Global, non-randomized, phase 2 study Adjuvant/ Neoadjuvant period A Neoadjuvant period B consolidation period Durvalumab + MDT Surgery Baseline MDT Resectable⁺ investigator's choice Durvalumab + reassessment Durvalumab resectability of platinum-based CT investigator's choice Restaging/ monotherapy assessment* Q3W for 1-2 cycles of platinum-based CT optional Q4W for 12 cycles (resectable or Q3W for 2 cycles pathologic borderline resectable) confirmation CRT Unresectable Key inclusion criteria and study requirements Primary endpoint Aged ≥18 years Resection rate, defined as proportion of all patients (FAS) who underwent definitive surgery Previously untreated Secondary endpoints Pathologically confirmed, resectable or borderline Resection rate in patients deemed resectable/borderline resectable at baseline resectable stage IIB-IIIB NSCLC (AJCC 8th edition¹) Surgical outcomes in patients who underwent surgery EGFR/ALK wild type (per local test) ORR in patients deemed resectable/unresectable at MDT reassessment WHO/ECOG PS 0-1 pCR and EFS in all patients (FAS) and patients deemed resectable at MDT reassessment At least 1 target lesion not previously irradiated PFS in patients deemed unresectable at MDT reassessment Pre-operative RT not allowed Safety *MDT comprised a medical/pulmonary oncologist, thoracic surgeon, radiation oncologist, and pathologist at a minimum; resectable/borderline resectable status determined per MDT decision based on baseline available assessments. Patients who were deemed eligible for surgery at MDT evaluation but then deemed unresectable/progressed locally at the pre-surgery assessments entered the unresectable cohort. Five fractions/week for ~6 weeks (± 3 days) (total 60 Gy + 10%). Efficacy outcomes are reported, unless otherwise indicated, according to prespecified analysis populations except for pCR (assessed per local pathology review), which was not prespecified for analysis in all patients. AJCC, American Joint Committee on Cancer; ECOG, Eastern Cooperative Oncology Group; FAS, full analysis set (i.e., all patients who received at least one dose of study intervention); Gy, gray; ORR, objective response rate; PS, performance status; QXW, once every X weeks; RT, radiotherapy; WHO, World Health Organization. 1. Amin MB, et al. AJCC Cancer Staging Manual. 8th ed. New York, NY: Springer; 2017. --- [Slide 3] IASLC 2026 World Conference SEPTEMBER 12 - 15, 2026 05 min 25s 2026 on Lung Cancer SEOUL, REPUBLIC OF KOREA Resection rates and outcomes (FAS) The overall resection rate was 74.6% and most patients had R0 resection 100 Resection rate, 80 % (95% CI)*,⁺ 60 40 20 74.6% 81.5% 62.0% (66.7-81.6) (72.1-88.9) (47.2-75.3) 0 All patients Resectable Borderline resectable (N=142) at baseline (n=92) at baseline (n=50) 2.8% 0.9% 4.0% 3.2% (0.6-8.0) (0.0-5.1) (0.8-11.2) 0% (0.1-16.7) (0.0-4.8) 0% Resection (0.0-11.2) outcomes, % (95% CI)* 96.2% 96.0% 96.8% (90.6-99.0) (88.8-99.2) (83.3-99.9) R0 R1 R2 R0 R1 R2 R0 R1 R2 Resected cohort: all patients Resected cohort: resectable at Resected cohort: borderline (n=106) baseline (n=75) resectable at baseline (n=31) DCO, 12 January 2026. *Defined as the proportion of patients who started resection. Cls calculated by Clopper-Pearson exact method. Percentages based on the number of patients who started resection surgery as the denominator. CI, confidence interval. 9 --- [Slide 4] IASLC 2026 World Conference SEPTEMBER 12 - 15, 2026 03 min 37s on Lung Cancer SEOUL, REPUBLIC OF KOREA pCR EFS by pCR 27.3% of all patients resectable at MDT 12-month EFS was higher in patients with vs reassessment had pCR, including 31.3% without pCR (100% VS 89.8%) who were resectable at baseline Resectable at pCR No pCR MDT reassessment No. events / no. patients (%) 0/33 (0) 9/73 (12.3) 12-month EFS, % (95% CI)* 100.0 (100.0-100.0) 89.8 (79.6-95.0) 30 1.00 FAS 0.75 pCR rate, % (95% CI)* 20 Probability of EFS 0.50 10 0.25 23.2% 31.3% 18.4% 27.3% 0.00 (16.6-31.1) (21.6-42.4) (7.7-34.3) (19.6-36.1) 0 3 6 9 12 15 18 21 0 All patients Resectable Borderline Resectable No. at risk: Time from first dose (months) (N=142) at baseline resectable at cohort pCR 33 33 30 19 10 0 0 0 (n=83) baseline (n=121) No pCR 73 73 64 50 30 5 3 0 (n=38) DCO, 12 January 2026. *95% Cls calculated by Clopper-Pearson exact method. Median follow-up (range) in censored patients with VS without pCR: 10.4 (5.3-14.1) VS 11.4 (4.6-20.2) months. 13 ***
Hidehito HORINOUCHI
MDT-BRIDGE — shared slides
WCLC 2026 · 2026-09-13
View on X
[Slide 1] IASLC 2026 World Conference SEPTEMBER 12 - 15, 2026 08 min 35s on Lung Cancer SEOUL, REPUBLIC OF KOREA MDT-BRIDGE study design Global, non-randomized, phase 2 study Adjuvant/ Neoadjuvant period A Neoadjuvant period B consolidation period Durvalumab + MDT Surgery Baseline MDT Resectable+ investigator's choice Durvalumab + reassessment Durvalumab resectability of platinum-based CT investigator's choice Restaging/ monotherapy assessment* Q3W for 1-2 cycles of platinum-based CT optional Q4W for 12 cycles (resectable or Q3W for 2 cycles pathologic borderline resectable) confirmation CRT Unresectable Key inclusion criteria and study requirements Primary endpoint Aged ≥18 years Resection rate, defined as proportion of all patients (FAS) who underwent definitive surgery Previously untreated Secondary endpoints Pathologically confirmed, resectable or borderline Resection rate in patients deemed resectable/borderline resectable at baseline resectable stage IIB-IIIB NSCLC (AJCC 8th edition¹) Surgical outcomes in patients who underwent surgery EGFR/ALK wild type (per local test) ORR in patients deemed resectable/unresectable at MDT reassessment WHO/ECOG PS 0-1 pCR and EFS in all patients (FAS) and patients deemed resectable at MDT reassessment At least 1 target lesion not previously irradiated PFS in patients deemed unresectable at MDT reassessment Pre-operative RT not allowed Safety *MDT comprised a medical/pulmonary oncologist, thoracic surgeon, radiation oncologist, and pathologist at a minimum; resectable/borderline resectable status determined per MDT decision based on baseline available assessments. Patients who were deemed eligible for surgery at MDT evaluation but then deemed unresectable/progressed locally at the pre-surgery assessments entered the unresectable cohort. Five fractions/week for ~6 weeks (± 3 days) (total 60 Gy ± 10%). Efficacy outcomes are reported, unless otherwise indicated, according to prespecified analysis populations except for pCR (assessed per local pathology review), which was not prespecified for analysis in all patients. AJCC, American Joint Committee on Cancer; ECOG, Eastern Cooperative Oncology Group; FAS, full analysis set (i.e., all patients who received at least one dose of study intervention); Gy, gray; ORR, objective response rate; PS, performance status; QXW, once every X weeks; RT, radiotherapy; WHO, World Health Organization. 1. Amin MB, et al. AJCC Cancer Staging Manual. 8th ed. New York, NY: Springer; 2017. --- [Slide 2] IASLC 2026 World Conference SEPTEMBER 12 - 15, 2026 05 min 49s 2026 on Lung Cancer SEOUL, REPUBLIC OF KOREA Changes in resectability assessments and local treatment (FAS) After 2 cycles of neoadjuvant durvalumab + CT, most patients, including those who were borderline resectable at baseline, were deemed resectable at MDT reassessment MDT reassessment, Adjuvant or consolidation Baseline MDT Local Tx durvalumab post cycle 2* assessment Resected 94 Adjuvant Tx 82 Resectable 92 120 106 Yi 106+ 12 38 12 No adjuvant Tx 7 Borderline CRT 50 23 23 Consolidation Tx resectable 25 7 9 2 2 No consolidation Tx 18 11 No local Tx Unresectable 1 20 2 11 cCRT: 21 sCRT: 4 1 2 Not reassessed 2 92.3% had either surgery or CRT after neoadjuvant durvalumab + CT DCO, 12 January 2026. *Two patients discontinued and were not reassessed: one deemed resectable and one deemed borderline resectable at baseline. The patient who was resectable at baseline was included in the 'Resectable' cohort and the patient who was borderline resectable at baseline was included in the 'Unresectable' cohort, as prespecified in the statistical analysis plan. Two patients did not complete surgical resection as intended due to the absence of primary tumor in the lung parenchyma; only lymph nodes were removed. c/sCRT, concurrent/sequential CRT; Tx, treatment. Summaries of MDT assessment cohorts and local treatment available via OR code. --- [Slide 3] IASLC 2026 World Conference SEPTEMBER 12 - 15, 2026 06 min 22s 2026 on Lung Cancer SEOUL, REPUBLIC OF KOREA Reasons for borderline resectability status at baseline (FAS) Tumor T and/or N status primarily drove borderline resectability assessment at baseline, and R0 resection was uncertain in approximately one-quarter of these patients Criteria leading to borderline resectability MDT assessment of the potential for R0 resection 60 assessment at baseline (n=50)⁺ before neoadjuvant treatment Resectable Borderline resectable 50 at baseline (n=92) at baseline (n=50) 3,3% Proportion of patients, % 40 28,0% 30 50,0% 72,0% 96,7% 20 32,0% 10 8,0% 6,0% 4,0% R0 possible R0 uncertain 0 Only T Only N Both T and Neither T or Missing status status N status N status DCO, 12 January 2026. *As reported by the MDT or investigators. Percentages calculated based on the number of patients deemed borderline resectable at baseline as the denominator. 7 --- [Slide 4] IASLC 2026 World Conference SEPTEMBER 12 - 15, 2026 04 min 05s 2026 on Lung Cancer SEOUL, REPUBLIC OF KOREA EFS and PFS in subgroups of interest EFS in patients resectable at MDT PFS in patients unresectable at MDT reassessment and in resected patients reassessment and in CRT-treated patients Resectable Resected Unresectable CRT-treated No. events / no. patients (%) 15/121 (12.4) 9/106 (8.5) No. events / no. patients (%) 5/21 (23.8) 6/25 (24.0) 12-month EFS, % (95% CI)* 90.1 (82.8-94.4) 92.9 (85.5-96.6) 12-month PFS, % (95% CI)** 75.1 (45.2-90.2) 85.0 (59.8-95.0) 1.00 1.00 Probability of EFS 0.75 0.75 0.50 Probability of PFS 0.50 0.25 0.25 0.00 0.00 0 3 6 9 12 15 18 21 0 3 6 9 12 15 18 No. at risk: Time from first dose (months) No. at risk: Time from first dose (months) Resectable 121 117 101 75 43 5 3 0 Unresectable 21 18 12 8 5 1 0 Resected 106 106 94 69 40 5 3 0 CRT-treated 25 22 17 12 8 1 0 DCO, 12 January 2026. *12-month rate calculated by Kaplan-Meier method, with 95% Cls calculated by Brookmeyer-Crowley method. Based on 23.8% maturity and median PFS follow-up of 7.3 months in all (censored) patients deemed unresectable at reassessment, with PFS defined as the time from the first dose of any study treatment until PD, assessed by the investigator per RECIST version 1.1, or death (by any cause in the absence of progression) regardless of whether the patient withdrew from therapy or received another anticancer therapy prior to progression. ORR at pre-surgery/pre-CRT available via OR code. 12 00 ...

What Physicians Said

Alfredo Addeo MD
Alfredo Addeo MD@Alfdoc2

🔥 Outstanding piece of work published today in Nature Medicine! Huge congratulations to @MartinReck2 ,@NadalErnest , @DoctorJSpicer and @AndrearicFili , and the entire MDT-BRIDGE team on this important publication! 👏👏 The phase II MDT-BRIDGE trial, investigating neoadjuvant durvalumab plus chemotherapy in resectable or borderline resectable NSCLC, tackles a clinically relevant question: how can we push the boundaries of multidisciplinary treatment and offer more patients a chance of curative-intent therapy? This is exactly the kind of collaborative clinical research we need: challenging established boundaries, asking meaningful questions, and ultimately striving to improve outcomes for our patients. Congratulations to everyone involved! 👏 🔗 https://t.co/ZSkztTwXDK Happy to continue sharing exciting advances in lung cancer research as an #ESMOAmbassadors #ESMO26 #NatureMedicine #LungCancer #NSCLC #ThoracicOncology #Immunotherapy #ClinicalResearch #MultidisciplinaryCare #CancerResearch

👁 12K ♡ 88 ↻ 32 Oct 26, 2026
Drew Moghanaki
Drew Moghanaki@DrewMoghanaki

I've been reflecting on the recently published MDT-BRIDGE study and what its results tell us about the importance of multidisciplinary treatment decisions for patients with resectable NSCLC. As a radiation oncologist who has long believed that chemoradiotherapy (CRT) can achieve outcomes comparable to surgery in selected patients with low-volume stage II–III NSCLC, I see an important message in the recent publication. https://t.co/Lj1g5X8qT5 MDT-BRIDGE enrolled 142 operable patients with stage IIB–IIIB NSCLC, including 92 classified as resectable and 50 as borderline resectable. All were technically resectable, yet the borderline group was deemed more challenging to resect. Importantly, radiation oncologists participated in multidisciplinary team (MDT) assessments both before treatment and after two cycles of neoadjuvant chemoimmunotherapy. This distinguishes MDT-BRIDGE from the treatment-selection pathways commonly associated with phase III neoadjuvant chemoimmunotherapy trials, in which medical oncologists and thoracic surgeons generally drove decisions about systemic therapy followed by resection. Such an approach has been associated with 20% of patients not undergoing planned surgery, with RWE studies reporting even higher surgery-aborted rates, exceeding 40%. This begs the question of whether earlier radiation oncologist involvement can reduce the number of patients who ultimately receive no surgery or curative-intent local therapy. The MDT-BRIDGE results offer an encouraging signal. Of the 142 patients who began neoadjuvant tx: - 106 (74.6%) proceeded to surgery - 25 (17.6%) received CRT instead - Only 11 (7.7%) received neither Remarkably, all 25 patients redirected to CRT completed their treatment, and 23 (92%) subsequently initiated consolidation durvalumab. Thus, 92.3% of patients received curative-intent local therapy, despite more than one-third initially being classified as borderline resectable. These findings highlight the potential value of an MDT that includes a radiation oncologist empowered to reassess the original surgical plan and redirect patients to CRT when resection is no longer feasible or appropriate. Notably, the resulting 7.7% rate of patients receiving no local therapy was substantially lower than the approximately 20% surgical attrition rates reported in prior phase III neoadjuvant trials enrolling similar patients. Of course, MDT-BRIDGE was a single-arm phase II study, and its results do not establish the impact of radiation oncologist participation on the relatively low rate of local therapy attrition. Nevertheless, the findings raise an important hypothesis worthy of further study. Especially, since previous studies for stage I NSCLC have demonstrated better surgical outcomes at institutions offering both surgery and SBRT, suggesting that access to alternative local therapies may improve patient selection and outMA takeawaycomes. https://t.co/iD8HZNAuDn https://t.co/SzC08F6hIR My updated takeaway from MDT-BRIDGE is that a radiation oncologist's value in the MDT extends well beyond delivering radiotherapy. It includes helping colleagues and patients navigate treatment decisions, reassessing the feasibility of competing approaches, and preserving opportunities for cure when the original plan changes. Even when surgery is the preferred initial strategy. I've seen this work incredibly well at my institution, and hope it's how all resectable pts are managed worldwide. For those interested in exploring the broader evidence supporting the value of MDT cancer care, I recommend this excellent review, published in 2024:

👁 2K ♡ 23 ↻ 8 Nov 12, 2026
Hidehito HORINOUCHI
Hidehito HORINOUCHI@HHorinouchi

🆙#ESMO26 Rapid Oral: #LCSM Non-Mets 🔥MDT-BRIDGE: ctDNA Clearance (CL) During Neoadjuvant Treatment (Neoadj Tx) and Its Association With Outcomes in Patients (Pts) With Resectable/Borderline Resectable Stage IIB–IIIB NSCLC 🎙️ @DoctorJSpicer 🔢LBA62 🎯ctDNA CL at C2D1 Had 83.3% PPV for pCR 🎯Pre-Surgery CL: pCR 76.0% vs Non-pCR 20.9% 🎯No EFS Events in Resected Pts With CL vs 12-Mo EFS 88.9% Without CL (n=107) ☑️NCT05925530 🔗 https://t.co/a1n3LKVbtq @OncoAlert @Larvol @myESMO @IASLC

👁 3K ♡ 12 ↻ 7 Oct 26, 2026
Hidehito HORINOUCHI
Hidehito HORINOUCHI@HHorinouchi

🔥MDT-BRIDGE: Neoadjuvant durvalumab + chemo in resectable/borderline resectable NSCLC — MDT-guided adaptive approach 🆙 @NatureMedicine #ESMO26 🎯ctDNA CL at C2D1 Had 83.3% PPV for pCR 🎯Pre-Surgery CL: pCR 76.0% vs Non-pCR 20.9% 🎯No EFS Events in Resected Pts With CL vs 12-Mo EFS 88.9% Without CL (n=107) 🎙 @MartinReck2 @DoctorJSpicer ☑️NCT05925530 #LCSM @OncoAlert @Larvol @myESMO @IASLC

👁 2K ♡ 26 ↻ 15 Oct 26, 2026
Dr. Antonio Calles 🫁🚭
Dr. Antonio Calles 🫁🚭@Tony_Calles

Proud participation of our hospital 🏥 in the MDT-BRIDGE leading by @rosaalvarezal with a terrific publication. Congrats!!!! #ESMO26 #LCSM

👁 578 ♡ 9 ↻ 3 Oct 26, 2026
Jeff Ryckman
Jeff Ryckman@jryckman3

Congrats to Reck, Spicer, Filippi and team on the full MDT-BRIDGE paper in Nature Medicine! Really appreciate seeing the RT protocol and full denominators alongside the ASTRO results. 👏 This single-arm ph2 enrolled 142 pts with resectable or borderline-resectable stage IIB-selected IIIB, EGFR/ALK-wt NSCLC. Durvalumab + platinum chemo x2c→ MDT reassessment→ additional chemoimmunotherapy and surgery, or CRT, followed by durvalumab. Resection was 74.6% (95CI 66.7-81.6), with R0 in 96.2% of those who started surgery. pCR was 27.3% in the resectable analysis cohort. The 12-mo EFS estimates are 88.5% overall and 90.1% in that resectable cohort. Different denominators, same readout. The RT protocol details are useful: nominal 60/30 (60 Gy ±10% in 2 Gy fx), 5 fx/wk for ~6 wk, concurrent or sequential platinum chemo. SBRT was not allowed. IMRT with daily CBCT was preferred, then consolidation durvalumab q4w up to 12c. All 25 pts who started CRT completed it: 21 concurrent, 4 sequential. 23 received consolidation durvalumab. The post hoc CRT-treated analysis estimated 12-mo PFS at 85% (95CI 59.8-95.0), measured from the FIRST study-treatment dose, including induction. CRT-period G3/4 AEs were 28%; pneumonitis 8% (2 pts, both G2). During consolidation, G3/4 AEs were 17.4%, AE discontinuation 13%, and pneumonitis 8.7% (G1/2). One cardiac-failure AE death occurred during consolidation; the paper reports no treatment-related AE deaths in that period. The safety windows extend beyond treatment delivery and can overlap. The ESMO ctDNA analysis adds an interesting association. Pre-Sx/CRT clearance occurred in 33/90 evaluable pts (36.7%). C2D1 clearance had an 83.3% PPV for pCR (95CI 43.6-99.1). Among resected pts, no EFS events occurred with pre-Sx clearance (n=28); 12-mo EFS without clearance was 88.9% (n=40). In CRT-treated pts, 12-mo PFS was 100% with pre-CRT clearance vs 77.5% without. The paper now supplies those subgroup sizes: just 4 vs 16 pts, with 2 vs 6 at risk at 12 mo. One later event occurred in the clearance group, so 100% is a timepoint estimate, not no events throughout follow-up. Useful prospective evidence that patients can reach definitive CRT after starting on a surgical pathway. The unanswered question remains who benefits from that sequence versus going directly to CRT or selecting for NAC-ICO with intent for organ preservation. Selected cohorts, immature EFS/PFS and no reported OS cannot settle that, and ctDNA does not yet tell us which local therapy to choose or omit. https://t.co/he6OT4TsJ5 https://t.co/LaiIFjAdII #radonc #ESMO26 #LCSM

👁 2K ♡ 26 ↻ 10 Oct 26, 2026
Yago Garitaonaindía
Yago Garitaonaindía@YGaritaonaindia

Compelling results from MDT-BRIDGE #WCLC26 Two personal takeaways/ideas Stop calling full resectability upfront: assess it after neoadjuvant chemo-IO, when the tumour has already shown you what it does. ➕ the value is in the sequence, not just the drug. Prime with IO, let the immune response settle, then irradiate. Personal opinion: it will hold in upfront unresectable disease too (APOLO). 👇👇👇

👁 1.1K 2026-09-13
Stephen V Liu, MD
Stephen V Liu, MD@StephenVLiu

Dr. @MartinReck2 presents MDT-Bridge at #WCLC26: pts with resectable or borderline resectable NSCLC received 1-2 cycles of durvalumab + chemotherapy then surgery if resectable or CRT if not, followed by adjuvant/consolidation durvalumab. Of those with borderline resectable NSCLC, 62% underwent resection (97% R0). Overall resection rate 75% and 27% pCR rate.

👀 5,5882026-09-13
Hidehito HORINOUCHI
Hidehito HORINOUCHI@HHorinouchi

🆙#WCLC26 #LCSM Oral Session 🔥MDT-BRIDGE: Neoadjuvant Durvalumab + Chemotherapy for Resectable/Borderline Resectable Stage IIB-IIIB NSCLC 🎙️ @MartinReck2 🔢OA04.02 🎯Resection Rate 74.6%; pCR 27.3% and 12-Mo EFS 90.1% in Resectable Cohort ☑️NCT05925530 🔗 https://t.co/rN1vqVmvgD @OncoAlert @Larvol @IASLC

👀 2,6042026-09-13
Uğur Özkerim
Uğur Özkerim@UOzkerim

#WCLC26 | MDT-BRIDGE Neoadjuvant durvalumab + platinum-based chemotherapy in resectable/borderline resectable stage IIB–IIIB NSCLC: • Resection rate: 74.6% • pCR: 27.3% • 12-month EFS: 90.1% in the resectable cohort • 92.3% of patients underwent either surgery or CRT after neoadjuvant treatment. An interesting MDT-based approach integrating surgery and CRT according to reassessment @OncoAlert @ManuelDomine @weoncologists @OpenMedKate

👀 1,4532026-09-13
MV Chandrakanth
MV Chandrakanth@ChandrakanthMv

MDT-BRIDGE: Treat First. Decide Surgery Later? A simple but interesting concept in locally advanced NSCLC: • Start with chemo-immunotherapy rather than locking in the local treatment upfront. • Then reassess in the MDT. • If resectable → surgery. • If not resectable → definitive chemoradiotherapy. • Continue durvalumab after either pathway. The idea: Treat → Reassess → Choose the best curative-intent path. Reference: Reck M et al. MDT-BRIDGE Primary Analysis. WCLC 2026; OA04.02. #MVOnco #WCLC2026 #MDTBRIDGE #NSCLC #LungCancer

👀 1,2872026-09-12
Diego A. Díaz-García
Diego A. Díaz-García@diegoadiazg

🫁 MDT-BRIDGE: a perioperative-to-definitive strategy for stage IIB-IIIB NSCLC. @MartinReck2 Neoadjuvant durvalumab + chemotherapy followed by surgery or CRT achieved: • Resection rate: 74.6% • R0 resection: 96.2% • pCR: 27.3% • 12-month EFS: 90.1% in resectable patients • 12-month PFS: 75.1% in patients becoming unresectable Overall, 92.3% received surgery or CRT, supporting multidisciplinary reassessment to maintain curative-intent treatment. #CánCare #NSCLC #ThoracicOncology #Immunotherapy #Durvalumab #WCLC26 @IASLC

👀 7182026-09-13
Tejas Patil
Tejas Patil@TejasPatilMD

8. MDT-BRIDGE ⭐️Neoadjuvant durvalumab + chemo --> followed by serial MDT reassessment allowed 92.3% of patients to receive to curative-intent surgery or CRT, even with nearly a third of pts having borderline resectable disease 🗝️ KEY INSIGHTS: - 74.6% overall resection rate (n = 142) - 96.2% R0 resection - 27.3% pCR among patients remaining resectable - 90.1% 12-mo EFS in the resectable cohort - 75.1% 12-mo PFS in those converted to CRT ⚡️The interesting concept here isn't prior neoadjuvant exposure. Rather it’s the dynamic treatment strategy, allowing patients to transition from surgery to definitive CRT rather than abandoning curative intent when resectability changes. This will be a heavily debated study. @lcsmchat @OncoAlert @OncLive @LungCancerEu @Lung_Cancers @MedwatchHQ

👀 6712026-09-11

About the MDT-BRIDGE Trial

Locally advanced NSCLC forces an upfront call — operable or not — that determines a patient's entire pathway. MDT-BRIDGE inverts that: give 1–2 cycles of durvalumab plus chemotherapy first, then let the multidisciplinary team decide with response information in hand. At WCLC 2026 Martin Reck presented the primary analysis: nearly three-quarters of all patients were resected (96.2% R0), three-quarters of the borderline group converted to resectable, and 92.3% reached curative-intent local therapy of one kind or the other.

Physicians called out the pragmatism: the design mirrors how tumor boards actually think, and offers a protocolized route for the borderline group that trials usually exclude. Patient selection and longer follow-up remain the open questions KOLs flagged.

Trial Methodology & Results

Study Design

Phase II adaptive: neoadjuvant durvalumab + chemo (1–2 cycles) → MDT reassessment → surgery or definitive CRT → adjuvant/consolidation durvalumab. (WCLC 2026 OA04.02 via verbatim captures)

Population

Resectable and borderline-resectable stage IIB–IIIB NSCLC; n=142 in the presented analysis. (Verbatim KOL captures)

Endpoints

Resection rate, R0 rate, pCR, EFS; 12-month EFS 90.1% in the resectable cohort. (Verbatim KOL captures)

Presenter

Martin Reck, MD — WCLC 2026 oral OA04.02. (Verbatim KOL captures)

Surgical and pathological outcomes

Of the 142 treated patients (full analysis set), 74.6% underwent resection; the R0 rate of 96.2% is among those resected, and pCR of 27.3% is in the full analysis set. Among borderline-resectable patients, 76% converted to resectable after induction, and 92.3% of all patients received curative-intent surgery or chemoradiotherapy. Safety and perioperative-morbidity tables are in the primary presentation and are not reproduced here. (WCLC 2026 OA04.02, via verbatim physician captures: Patil, Özkerim, Díaz-García)

Resection 74.6% · R0 96.2% · pCR 27.3%
Source: WCLC 2026 OA04.02 (verbatim KOL captures) ↗

Event-free survival

12-month EFS was 90.1% in the resectable cohort (12-month PFS 75.1% reported for the definitive-CRT pathway per physician capture) — early but supportive of the bridging strategy; longer follow-up pending. (WCLC 2026 OA04.02 via verbatim captures: Horinouchi, Díaz-García)

12-mo EFS 90.1% (resectable cohort)
Source: WCLC 2026 OA04.02 (verbatim KOL captures) ↗

MDT-BRIDGE FAQ

What is the MDT-BRIDGE trial?

MDT-BRIDGE (NCT05925530) is an AstraZeneca phase II study in resectable and borderline-resectable stage IIB–IIIB NSCLC. Patients receive 1–2 cycles of neoadjuvant durvalumab plus chemotherapy, then a multidisciplinary team reassesses resectability: resectable patients go to surgery, others to definitive chemoradiotherapy, with adjuvant or consolidation durvalumab afterward.

What did MDT-BRIDGE show at WCLC 2026?

In the primary analysis presented by Martin Reck (OA04.02, 142 treated patients): a resection rate of 74.6% of all treated patients, R0 in 96.2% of those resected, pathological complete response in 27.3%, 12-month event-free survival of 90.1% among patients deemed resectable at MDT reassessment, and 92.3% of all patients reaching curative-intent surgery or CRT. About 76% of borderline-resectable patients became resectable after induction. Safety and perioperative-morbidity data are in the primary presentation and not reproduced on this page.

Why do physicians find the design notable?

It treats resectability as a dynamic, treatment-modifiable state judged after induction therapy rather than a fixed baseline label — matching how multidisciplinary tumor boards actually work and creating a protocolized pathway for borderline patients whom conventional trials exclude.

Is this an approved treatment approach?

No. The MDT-BRIDGE strategy is investigational. Durvalumab (Imfinzi, AstraZeneca) is approved in other NSCLC settings — consolidation after chemoradiotherapy in unresectable stage III (PACIFIC) and perioperative use (AEGEAN) — but the adaptive bridging paradigm itself is not an approved regimen.

What are the caveats?

Phase II size, no randomized comparator, and the patient-selection question physicians raised — plus the need for longer event-free and overall survival follow-up before the strategy can claim practice-changing status.

Key KOL Sentiments

KOLComment (verbatim)SentimentDate
Yago GaritaonaindíaCompelling results from MDT-BRIDGE #WCLC26 Two personal takeaways/ideas Stop calling full resectability upfront: assess it after neoadjuvant chemo-IO, when the tumour has already shown you what it does. ➕ the value is in the sequence, not just the drug. Prime with IO, let the immune response settle, then irradiate. Personal opinion: it will hold in upfront unresectable disease too (APOLO). 👇👇👇● POSITIVE
Stephen V Liu, MD
@StephenVLiu
Dr. @MartinReck2 presents MDT-Bridge at #WCLC26: pts with resectable or borderline resectable NSCLC received 1-2 cycles of durvalumab + chemotherapy then surgery if resectable or CRT if not, followed by adjuvant/consolidation durvalumab. Of those with borderline resectable NSCLC, 62% underwent resection (97% R0). Overall resection rate 75% and 27% pCR rate.Neutral2026-09-13
Hidehito HORINOUCHI
@HHorinouchi
🆙#WCLC26 #LCSM Oral Session 🔥MDT-BRIDGE: Neoadjuvant Durvalumab + Chemotherapy for Resectable/Borderline Resectable Stage IIB-IIIB NSCLC 🎙️ @MartinReck2 🔢OA04.02 🎯Resection Rate 74.6%; pCR 27.3% and 12-Mo EFS 90.1% in Resectable Cohort ☑️NCT05925530 🔗 https://t.co/rN1vqVmvgD @OncoAlert @Larvol @IASLCNeutral2026-09-13
Uğur Özkerim
@UOzkerim
#WCLC26 | MDT-BRIDGE Neoadjuvant durvalumab + platinum-based chemotherapy in resectable/borderline resectable stage IIB–IIIB NSCLC: • Resection rate: 74.6% • pCR: 27.3% • 12-month EFS: 90.1% in the resectable cohort • 92.3% of patients underwent either surgery or CRT after neoadjuvant treatment. An interesting MDT-based approach integrating surgery and CRT according to reassessment @OncoAlert @ManuelDomine @weoncologists @OpenMedKateNeutral2026-09-13
MV Chandrakanth
@ChandrakanthMv
MDT-BRIDGE: Treat First. Decide Surgery Later? A simple but interesting concept in locally advanced NSCLC: • Start with chemo-immunotherapy rather than locking in the local treatment upfront. • Then reassess in the MDT. • If resectable → surgery. • If not resectable → definitive chemoradiotherapy. • Continue durvalumab after either pathway. The idea: Treat → Reassess → Choose the best curative-intent path. Reference: Reck M et al. MDT-BRIDGE Primary Analysis. WCLC 2026; OA04.02. #MVOnco #WCLC2026 #MDTBRIDGE #NSCLC #LungCancerNeutral2026-09-12
Diego A. Díaz-García
@diegoadiazg
🫁 MDT-BRIDGE: a perioperative-to-definitive strategy for stage IIB-IIIB NSCLC. @MartinReck2 Neoadjuvant durvalumab + chemotherapy followed by surgery or CRT achieved: • Resection rate: 74.6% • R0 resection: 96.2% • pCR: 27.3% • 12-month EFS: 90.1% in resectable patients • 12-month PFS: 75.1% in patients becoming unresectable Overall, 92.3% received surgery or CRT, supporting multidisciplinary reassessment to maintain curative-intent treatment. #CánCare #NSCLC #ThoracicOncology #Immunotherapy #Durvalumab #WCLC26 @IASLCNeutral2026-09-13
Tejas Patil
@TejasPatilMD
8. MDT-BRIDGE ⭐️Neoadjuvant durvalumab + chemo --> followed by serial MDT reassessment allowed 92.3% of patients to receive to curative-intent surgery or CRT, even with nearly a third of pts having borderline resectable disease 🗝️ KEY INSIGHTS: - 74.6% overall resection rate (n = 142) - 96.2% R0 resection - 27.3% pCR among patients remaining resectable - 90.1% 12-mo EFS in the resectable cohort - 75.1% 12-mo PFS in those converted to CRT ⚡️The interesting concept here isn't prior neoadjuvant exposure. Rather it’s the dynamic treatment strategy, allowing patients to transition from surgery to definitive CRT rather than abandoning curative intent when resectability changes. This will be a heavily debated study. @lcsmchat @OncoAlert @OncLive @LungCancerEu @Lung_Cancers @MedwatchHQNeutral2026-09-11
Free Access · KOL Pulse Intelligence

Track oncology’s top KOLs in your specialty

Create a free account, pick the tumor types you cover, and go beyond the tweet — the intelligence pharma teams use to map influence and prepare for engagement:

  • ✓Enhanced KOL profiles
  • ✓Pharma influence & potential advisory-board patterns
  • ✓2025 Open Payments financial analysis
  • ✓Social-media sentiment & trend signals
Get free access — pick your specialty
Choose the tumor types you follow. No cost, unsubscribe anytime.

Compiled and reviewed by the KOL Pulse research team, led by Brian Shields, Founder, KOL Pulse. Last updated September 13, 2026. Every statistic carries its source label in place; every quote is verbatim from the physician's own post.